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Abstract
Background: The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the World Health
Organisation (WHO) in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem
globally by 2020. Mass drug administration (MDA) of antifilarial drugs is the principal strategy recommended for
global elimination. Kenya launched a National Programme for Elimination of Lymphatic Filariasis (NPELF) in Coast
Region in 2002. During the same year a longitudinal research project to monitor trends of LF infection during MDA
started in a highly endemic area in Malindi District. High coverage of insecticide treated nets (ITNs) in the coastal
region has been associated with dramatic decline in hospital admissions due to malaria; high usage of ITNs is also
expected to have an impact on LF infection, also transmitted by mosquitoes.
Results: Four rounds of MDA with diethylcarbamazine citrate (DEC) and albendazole were given to 8 study villages
over an 8-year period. Although annual MDA was not administered for several years the overall prevalence of
microfilariae declined significantly from 20.9% in 2002 to 0.9% in 2009. Similarly, the prevalence of filarial
antigenaemia declined from 34.6% in 2002 to 10.8% in 2009. All the examined children born since the start of the
programme were negative for filarial antigen in 2009.
Conclusions: Despite the fact that the study villages missed MDA in some of the years, significant reductions in
infection prevalence and intensity were observed at each survey. More importantly, there were no rebounds in
infection prevalence between treatment rounds. However, because of confounding variables such as insecticide-
treated bed nets (ITNs), it is difficult to attribute the reduction to MDA alone as ITNs can lead to a significant
reduction in exposure to filariasis vectors. The results indicate that national LF elimination programmes should be
encouraged to continue provision of MDA albeit constraints that may lead to missing of MDA in some years.
Background
The World Health Assembly (WHA) Resolution 50.29
made in 1997 called for elimination of lymphatic filaria-
sis (LF) as a public health problem [1]. Following this
resolution, the World Health Organization (WHO)
initiated the Global Programme to Eliminate LF
(GPELF) and rapid progress has been made since its
launching in 2000 [2-4]. The GPELF recommends that
consecutive annual rounds of mass drug administration
(MDA) be given to all eligible persons until interruption
of transmission is achieved. The recommended antifilar-
ial treatment is a combination of albendazole with either
diethylcarbamazine (DEC) or ivermectin (Mectizan).
Success of MDA depends on interruption of parasite
transmission by reducing the prevalence of microfilariae
circulating in blood of individuals living in endemic
areas [5].
In Kenya, LF is due to Wuchereria bancrofti and is
endemic in the coastal areas along the Indian Ocean
from Lamu District in the north to Msambweni District
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cal investigations in the Kenyan coastal region have
reported that Anopheles gambiae sensu lato, An. funes-
tus and Culex quinquefasciatus are the vectors involved
in transmission of LF [6,7]. On the east coast of Africa,
the urban mosquito, Culex quinquefasciatus,i sa n
important vector in cities and large urban settlements.
This mosquito is known to breed in a variety of stag-
nant water habitats where the water has been suffi-
ciently polluted like in cess pits and canals near houses
with long standing bathroom sewage water. As you
move inland, Anopheles mosquitoes become predomi-
nant and are the principal vectors in rural coastal vil-
lages on the east coast of Africa [8]. Since malaria is
also endemic in these setting there are intense efforts to
reduce transmission of the infection mainly through
increased distribution of insecticide-treated bed nets
(ITNs). In Kenya, nets are supplied to malaria endemic
communities through different sources including com-
mercial outlets, free distribution by local NGOs, and
national health programmes such as sale of highly subsi-
dized ITNs to pregnant women and children under five
through government health facilities.
Kenya initiated a National Programme for Elimination
of LF (NPELF) in 2002 which was launched in the larger
Kilifi District in 2002 and scaled up to include Malindi
and Kwale Districts in 2003. It is becoming more and
more apparent that national programmes to eliminate
lymphatic filariasis in sub-Saharan Africa may be faced
with challenges such as decreased funding and social
instability which may affect delivery of consecutive
rounds of MDA. The Kenyan LF elimination pro-
gramme, for example, has been unable to provide conse-
cutive annual rounds of MDA in the three districts and
scale up implementation to include the other endemic
districts mainly due to budgetary constraints. It is there-
fore necessary to monitor and evaluate the impact of
such inadvertently missed MDA rounds to provide
information that may be used to make evidence-based
programmatic decisions about such programmes.
The area along River Sabaki in Malindi District was
previously reported to be a major focus of bancroftian
filariasis [9]. In 2001, eight villages in this area were
selected for a pilot demonstration research project to
monitor the impact of MDA. Treatment followed WHO
guidelines using single-dose annual mass treatment with
DEC (6 mg/kg) plus albendazole (400 mg) [10]. Baseline
studies conducted in January/February 2002 in the area
collected data on microfilaraemia, filarial antigenaemia,
antifilarial antibodies and LF related disease manifesta-
tions [11,12]. Since implementation of the project, we
have been monitoring the impact of MDA [13]. This
study documented the impact of two consecutive annual
rounds of MDA followed by two other rounds not given
in consecutive years on LF infection (microfilaraemia
and antigenaemia).
Methods
Study area
This study was conducted in LF endemic villages situ-
ated along River Sabaki in Malindi District of Coast
Region, Kenya. The villages are typically rural and situ-
ated between 40 and 60 kilometres west of the Indian
Ocean in the Nyika plateau. The Nyika plateau is char-
acterized by hot and dry climate for most of the year
with low fertility brown sandy soils, low grassland and
thorny bush. The annual rainfall is between 500 mm
and 700 mm and the area is sparsely populated. This is
in contrast to the coastal plains and ranges near the
Indian Ocean which have hot and humid climate.
Description of the study area has previously been pro-
vided [11].
Study population and design
In 2001, eight villages located in the W. bancrofti ende-
mic area along River Sabaki were purposively selected
for this study. According to censuses conducted prior to
the first MDA the population of the villages ranged
between 600 - 900 persons. This was a longitudinal
s t u d yd e s i g n e dt of o l l o wu pa pproximately 200 indivi-
duals registered in each village. In each village, meetings
known in Kiswahili as baraza were conducted to sensi-
tize the members about the project. Individuals were
recruited into the study if 5 years or more, not severely
ill and if consent was given. Parasitological surveys to
monitor the impact of MDA were conducted periodi-
cally to determine changes in prevalence of microfilarae-
mia and filarial antigenaemia. The most recent post-
MDA survey was conducted in April/May 2009 in all
eight study villages. The protocol for this study was
reviewed and approved by the Scientific Steering and
Ethical Review Committees of the Kenya Medical
Research Institute (KEMRI). The Scientific Committee
reviewed the scientific content whereas the Ethics Com-
mittee looked at the ethical issues. Informed consent
w a ss u p p o s e dt ob ew r i t t e no na ni n f o r m e dc o n s e n t
form, but many study participants and/or their parents/
guardians were illiterate. In such situations the study
participant added a thumbprint after giving oral consent
and a literate witness, present during the informed con-
sent process, signed on the informed consent form on
behalf of the participant to confirm that the participant
gave consent.
Mass drug administration (MDA)
The first round of MDA was administered in the 8
study villages by the research team and Malindi District
hospital staff in April 2002. Subsequent rounds of
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NPELF which scaled up MDA geographical coverage to
include Malindi District as its third implementation unit
in 2003. Four rounds of MDA have been administered
to the eight villages in April 2002 (MDA1), September
2003 (MDA2), March 2005 (MDA3) and December
2008 (MDA4). We previously reported treatment
coverage for 2002 and 2003 MDAs among study partici-
pants in four study villages to be 83.4% (range 64.9 -
92.7%) and 80.3% (range 64.9 - 87.0%), respectively [13].
Table 1 summarizes treatment coverage among the
study group in 2005 and 2008 MDAs in the 8 study vil-
lages. To estimate treatment coverage, verbal interviews
were conducted with adult members of the study group
during household surveys. The NPELF was unable to
conduct MDA campaigns in 2004, 2006 and 2007 due
to financial constraints.
Blood collection, microfilariae examination and ICT test
Blood samples were collected from the study partici-
pants for microfilariae and circulating filarial antigen
examinations in February 2002 (baseline), March 2003,
July 2004, July 2007 and March 2009. Until the 2007
survey, two 100-μl finger prick blood samples were col-
lected from consenting study participants into hepari-
nized capillary tubes between 2000 h and 2400 h for
microfilariae detection and filarial antigen testing. One
blood sample was transferred into a tube containing 0.9
ml of 3% acetic acid solution and mixed gently. The
acetic acid diluted blood specimens were kept at room
temperature until the following day when examination
and counting of microfilariae were done using the
counting-chamber method [14].
The second finger prick blood was immediately tested
for filarial antigen using ICT test cards following manu-
facturer’s instructions. The ICT results were recorded as
either negative or positive after 10 minutes, and
indeterminate where the test bands were difficult for
two readers to classify as either positive or negative. In
2009 survey, venous blood samples were collected dur-
ing the day and using disposable micropipets, 100-μl
blood samples transferred onto the ICT test cards. Only
persons who were antigen-positive using the ICT test
were also tested for microfilaraemia. Approximately 3
ml of venous blood samples were collected from each
study participant into EDTA tubes in 2002 (pre-MDA),
2004 (post MDA2), and 2009 (post MDA4) surveys for
preparation of plasma samples to be used for serological
studies related to this study.
Mosquito net survey
Data used for assessing net ownership in the study area
come from a survey conducted in 2008 in four of the
study villages where mosquitoes were sampled in a
study to assess transmission of LF using molecular
methods. A structured questionnaire on ownership and
use of nets was administered to heads or other adult
members of households selected for mosquito sampling.
Data management and analysis
Data were recorded into data collection forms while in
the field and transferred into computer immediately
upon return to Nairobi. Statistical analyses were done
using SPSS statistical software version 12.0.1 (SPSS Inc.,
Chicago, IL, USA). The Pearson Chi-square (c
2)t e s t
was used to compare proportions including prevalence
of microfilaraemia and antigenaemia. Microfilarial
counts per ml of blood (mf/ml) were log-transformed
a n dt h eS t u d e n tt - t e s tu s e dt oc o m p a r em e a n sa tb a s e -
line and after the four rounds of MDA. The intensities
of microfilariae in the study villages were expressed as
geometric mean intensity (GMI) in all individuals exam-
ined for microfilariae (including those negative for
microfilariae). Differences were considered significant
when P was < 0.05. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) state-
ment was considered when reporting the findings of this
study [15].
Results
Changes in microfilaraemia
The overall prevalence of microfilaraemia in the eight
study villages in January 2002, before the implementa-
tion of MDA, was 20.9%. Since the introduction of
MDA in April 2002 a decrease in the prevalence of
microfilaraemia has been recorded in each post-MDA
survey. The changes in microfilariae prevalence in
each village during the study period are summarized in
Figure 1 and Table 2. When compared with the 2002
baseline (pre-MDA) data, the overall reduction in preva-
lence of microfilariae by 2009 was 95.7%. By 2007, there
Table 1 Treatment coverage in 2005 and 2008 MDAs
among registered study group
2005 (3
rd MDA) 2008 (4
th MDA)
Village No.
eligible
No. treated
(%)
No.
eligible
No. treated
(%)
Jilore 156 131 (84.0) 89 61 (68.5)
Marikano 256 234 (91.4) 108 91 (84.3)
Magongoloni 140 130 (92.9) 138 91 (65.9)
Mkondoni 244 230 (94.3) 126 108 (85.9)
Mwangatini 219 209 (95.4) 173 138 (79.8)
Burangi 229 224 (97.8) 160 132 (82.5)
Shakahola 212 200 (94.3) 160 68 (42.5)
Chakama 185 184 (99.5) 142 138 (97.2)
All 1641 1542 (94.0) 1096 827 (75.5)
Treatment coverage was estimated from interviews conducted on adult
members residing in study households.
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kama village and by 2009 there were no positive persons
detected in this and two other villages namely, Burangi
and Magongoloni. Further, of the total 1079 persons
examined in 2009, microfilariae were detected in only
10 individuals (0.9%). Additionally, the overall GMI of
microfilariae in all individuals examined for microfilariae
decreased by 98.5% (91.9 - 100%) from 2.75 mf/ml of
blood (2.18 - 3.40 mf/ml) in 2002 to 0.04 mf/ml (0 -
0.18 mf/ml) in 2009 (P < 0.001).
The ages of study participants in the respective survey
years were used to summarize changes in the prevalence
of microfilaraemia by age in the study villages. As shown
in Table 3, there was a significant decrease in
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Figure 1 Trends of prevalence of microfilariae (mf) and circulating filarial antigen (CFA) based on ICT test. During the 2009 survey, the
prevalences of microfilaraemia and antigenaemia were found to have significantly decreased by 95.7% (from 20.9% to 0.9%; P < 0.0001) and
68.8% (from 34.6% to 10.8%; P < 0.0001), respectively.
Table 2 Prevalence of microfilaraemia before and after 4 rounds of mass drug administration (MDA)
No. mf positive/No. examined (% mf positive)
Village 2002 (Pre-MDA) 95% CI (%) 2009 (Post 4 MDAs) 95% CI (%) % Decrease
Mwangatini 41/180 (22.8) 16.7 - 28.9 2/171 (1.2) 0.6 - 5.0 94.7
Burangi 44/194 (22.7) 16.8 - 28.6 0/159 (0.0) 0.0 - 2.1 100.0
Shakahola 28/157 (17.8) 11.8 - 23.8 2/156 (1.3) 0.0 - 3.7 92.7
Chakama 32/148 (21.6) 15.0 - 28.2 0/139 (0.0) - 100.0
Jilore 32/173 (18.5) 12.7 - 24.3 3/85 (3.5) 1.0 - 11.8 81.1
Marikano 44/192 (22.9) 17.0 - 28.8 2/106 (1.9) 0.0 - 5.7 91.7
Magongoloni 44/194 (22.7) 16.8 - 28.6 0/138 (0.0) 0.0 - 2.1 100.0
Mkondoni 32/181 (17.7) 12.1 - 23.3 1/125 (0.8) 0.0 - 4.9 95.5
All 297/1419 (20.9) 18.8 - 23.0 10/1079 (0.9) 1.2 - 2.6 95.7
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microfilariae positive person detected in the age group
b e l o w1 1y e a r so fa g ei nt h e2 0 0 7a n d2 0 0 9s u r v e y s .
Further, except for one person with microfilaraemia in
the 11-20 year age group, all the other microfilaraemic
persons were aged more than 30 years in the 2009 survey.
Changes filarial antigenaemia
Figure 1 summarizes the overa l lc h a n g ei nf i l a r i a la n t i -
gen prevalence based on ICT test in the study area. In
general, decrease in prevalence of filarial antigenaemia
was recorded during each follow up survey and roughly
paralleled the decrease in microfilaraemia. The preva-
lence of filarial antigenaemia declined from 34.6% in
February 2002 to 10.8% in May 2009, which represented
a 68.8% (range 57.2% - 77.5% in the individual villages)
reduction (P < 0.01). Details of changes in prevalence of
filarial antigenaemia in the eight study villages are sum-
marized in Table 4. Of 1096 persons examined for filar-
ial antigenaemia in the 2009 survey, however, there were
38 individuals with indeterminate results. The test bands
for these indeterminate cases appeared too faint and it
was difficult to record the results as either positive or
negative even after giving the cards to a second reader
(that is, there was no consensus). The changes in
prevalence of filarial antigenaemia by age are shown in
Table 5. Unlike microfilaraemia, antigenaemia was
detected in children aged less than 11 years in all the
years. The greatest decline in prevalence of antigenae-
mia was seen in individuals aged below 21 years old.
Effects of MDA on children born after implementation of
MDA
Children born since the implementation of MDA were
aged less than 8 years during the 2009 survey. This
group was compared with children of the same age
group at each parasitological survey as shown in Table
6. Before MDA in 2002, prevalence of microfilariae in
children below 8 years was 4.6%. There was no microfi-
lariae positive child below 8 years of age after two con-
secutive rounds of single-dose annual MDA given in
2002 and 2003. The prevalence of circulating filarial
antigen had also declined to 0% among children aged
below 8 years in 2009, but the decrease was not as fast
as that for microfilaraemia.
Mosquito net use
Around 70% of the people interviewed in the net survey
households conducted in four villages in 2008 reported
using a net the night prior to the study (Table 7). Addi-
tionally, more than 80% of the persons interviewed
reported using a mosquito net every night.
Table 3 Prevalence of microfilariae (mf) by age before and after 4 rounds of mass drug administration (MDA)
No. mf positive/No. examined (% mf positive)
Age group (years) 2002 (Pre-MDA) 95% CI 2009 (Post 4 MDAs) 95% CI % Decrease
< 11 30/350 (8.6) 5.6 - 11.5 0/220 (0.0) - 100.0
11 - 20 76/415 (18.3) 14.6 - 22.0 1/402 (0.2) 0.0 - 1.0 98.9
21 - 30 55/228 (24.1) 18.5 - 29.7 0/108 (0.0) - 100.0
31 - 40 43/150 (28.7) 21.5 - 35.9 3/127 (2.4) 0.0 - 5.1 91.6
41 - 50 40/136 (29.4) 21.7 - 37.1 3/106 (2.8) 0.0 - 5.9 90.5
> 50 53/140 (37.9) 29.9 - 45.9 3/116 (2.6) 0.0 - 5.5 93.1
All 297/1419 (20.9) 18.8 - 23.0 10/1079 (0.9) 0.3 - 1.5 95.7
Table 4 Prevalence of circulating filarial antigenaemia (CFA) before and after 4 rounds of mass drug administration
(MDA)
No. CFA positive/No. examined (% CFA positive)
Village 2002 (Pre-MDA) 95% CI (%) 2009 (Post 4 MDAs) 95% CI (%) % Decrease
Mwangatini 71/195 (36.4) 29.6 - 43.2 15/164 (9.1) 4.7 - 13.5 75.0
Burangi 69/199 (34.7) 28.1 - 41.3 12/153 (7.8) 3.6 - 12.0 77.5
Shakahola 51/157 (32.5) 25.2 - 39.8 13/156 (8.3) 4.0 - 12.6 74.5
Chakama 44/148 (29.7) 22.3 - 37.1 16/134 (11.9) 6.4 - 17.4 59.9
Jilore 66/172 (38.4) 31.1 - 45.7 13/83 (15.7) 7.9 - 23.5 59.1
Marikano 65/196 (33.2) 26.6 - 39.8 15/106 (14.2) 7.6 - 20.8 57.2
Magongoloni 85/198 (42.9) 36.0 - 49.8 20/138 (14.5) 8.6 - 20.4 66.2
Mkondoni 50/182 (27.5) 21.0 - 34.0 11/124 (8.9) 3.9 - 13.9 67.6
All 501/1447 (34.6) 32.1 - 37.1 115/1058 (10.8)* 8.9 - 12.7 68.8
*excluding 38 individuals who had indeterminate results in 2009
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The prevalence of both microfilaraemia and antigenae-
mia declined considerably in all the eight study villages
after the four rounds of MDA given during the 8-year
period of monitoring between February 2002 and May
2009. More pronounced decreases in the prevalence of
microfilariae and circulating filarial antigen were
observed in children less than 11 years of age compared
t ot h eo l d e ra g eg r o u p s ,a n db y2 0 0 7t h e r ew a sn o
microfilaraemic individual detected in this age group. A
recent study in Papua New Guinea showed that anti-
body rate also fell more rapidly after MDA in children
<11 years of age than in the total study population [16].
In the current study, with the exception of one person
with microfilaraemia in the 11-20 year age group, all the
other microfilaraemic persons were aged more than 30
years by 2009. Thus, the results of our study indicate
that microfilariae in the villages are currently confined
to older persons (aged above 30 years). This observation
suggests that the MDA given to the villages despite
missing several annual rounds had significant effects on
prevalence of LF and protected younger persons from
the infection. Further, the finding that the decrease in
microfilaraemia was greatest for children compared to
adults confirm the suitability of samples collected from
children for endpoint programme evaluations.
No microfilaraemic positive individuals were detected
in three villages (Chakama, Burangi, and Magongoloni)
in the 2009 survey but a significant microfilarial rate
was recorded in one village (Jilore, 3.5%). There is need
to conduct further investigations in such villages with
significant residual microfilarial rates to identify underly-
ing factors that might be hindering the decline in LF
infection. Such villages may have unique socio-cultural
and behavioural characteristics which may prevent some
members of the village to comply with MDA or have a
significant proportion of immigrants. Simulation models
suggest that the impact of mass treatment depends
strongly on several factors including compliance [17]. A
recent study conducted in Leogane, Haiti to identify fac-
tors responsible for continuing LF transmission after 7
rounds of MDA showed systematic noncompliance to
be statistically associated with infection status [18]. The
Haiti study concluded that high rates of noncompliance
maintain a reservoir of infection which drives LF trans-
mission. Our current method of assessing treatment
coverage has limitations because only study participants
are asked whether they took antifilarial drugs during the
last MDA. It is possible that this group is cooperative
because of social mobilization efforts designed to
enhance compliance with night blood sampling for
microfilarial detection and antigen testing. Such intense
social mobilization may also have improved compliance
to treatment with resultant greater reduction in LF
infection. A meeting conducted to understand why
some national programs have been more successful than
others highlighted the necessity to develop ‘compliance
profiles’ of villages to identify those groups of
Table 5 Prevalence of circulating filarial antigenaemia (CFA) by age group before and after mass drug administration
(MDA)
No. CFA positive/No. examined (% CFA positive)
Age group (years) 2002 (Pre-MDA) 95% CI (%) 2009 (Post MDA4) 95% CI (%) % Decrease
< 11 72/364 (19.8) 15.7 - 23.9 3/217 (1.4) 0.0 - 3.0 92.9
11 - 20 131/423 (31.0) 26.6 - 35.4 20/396 (5.1) 2.9 - 7.3 83.5
21 - 30 82/229 (35.8) 29.6 - 42.0 19/106 (17.9) 10.6 - 25.2 50.0
31 - 40 72/151 (47.7) 39.7 - 55.7 24/125 (19.2) 12.3 - 26.1 59.7
41 - 50 63/138 (45.7) 37.4 - 54.0 20/105 (19.0) 11.5 - 26.5 58.4
> 50 81/142 (57.0) 48.9 - 65.1 29/109 (26.6) 18.3 - 34.9 53.3
All 501/1447 (34.6) 32.1 - 37.1 115/1058 (10.8)* 8.9 - 12.7 68.8
*excluding 38 individuals who had indeterminate results in 2009
Table 6 Prevalence of microfilaraemia and antigenaemia in children aged below 8 years at each survey
No. positive/No. examined (%)
Month/year of survey mf 95% CI (%) CFA 95% CI (%)
February 2002 7/151 (4.6) 1.3 - 7.9 25/165 (15.2) 9.7 - 20.7
March 2003 1/85 (1.1) 0.0 - 3.3 4/85 (4.7) 0.2 - 9.2
July 2004 0/63 (0.0) - 1/64 (1.6) 0.0 - 4.7
July 2007 0/119 (0.0) - 2/120 (1.7) 0.0 - 4.0
May 2009 0/77 (0.0) - 0/76 (0.0) -
mf = microfilariae; CFA = circulating filarial antigen by ICT test
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during MDAs and then to determine the causes of this
non-compliance and effective approaches to overcoming
it [19]. Where operational research may indicate pro-
blems with village compliance, alternative social mobili-
zation strategies should also be developed to reach the
non-compliers to ensure success of the LF elimination
programme.
Although the overall prevalence of microfilariae had
decreased dramatically to 0.9% by 2009, the prevalence
of circulating filarial antigen, considered a marker of LF
infection and adult worm burden [20,21], was 10.8%. It
would be important to understand how adult worms
exposed to DEC/albendazole treatment are affected in
terms of reproductive potential. Thus although filarial
antigen positive individuals (without microfilariae) are
currently less important in terms of parasite transmis-
sion, it would be useful to continue monitoring changes
in this marker of LF infection. A total of 38 indetermi-
nate ICT results were also recorded during the 2009
survey which argue for the need to ensure the quality of
the diagnostic test(s) as the programme progresses
towards the endpoint phase. An ELISA assay based on
antifilarial IgG4 antibodies to the recombinant protein
Bm14, like the antigen-based tests, was indicated to be
highly specific for lymphatic filariasis and has been pro-
posed for long-term monitoring [22,23]. The Bm14 anti-
body test has been proposed to be an indicator of
filarial infection status and/or exposure to mosquito-
b o r n ei n f e c t i v el a r v a e[ 1 6 ]a n dt h u sm a yb eu s e f u li n
endpoint evaluation. Similarly, molecular xenomonitor-
ing (MX) has been proposed as an important diagnostic
tool especially for monitoring transmission during LF
elimination programmes [24-26]. The combination of
approaches as described in the evaluation of the national
programme in Egypt [27] provides a template for such
studies but may be constrained by both human and
financial constraints.
The decline in LF infection reported in our study is
dramatic considering that annual MDA was not sus-
tained as recommended by GPELF. The results of our
study are in contrast to those reported from a study in
Haiti where one missed round of MDA caused a consid-
erable rebound in microfilaraemia [28]. Two rounds of
MDA plus albendazole can reduce the intensity of
microfilariae in a highly endemic community by over
80% [16]. In areas where there is supplementary vector
control, the low levels of microfilarial intensities
achieved after one or two rounds of MDA can be main-
tained even in the absence of further MDA especially if
Anopheles mosquitoes are the principal vectors [29].
The results of mosquito net survey in our study area
indicate relatively high usage of nets in the study vil-
lages. No infective mosquitoes were found in an LF
endemic area of Papua New Guinea one year after 80%
of the community started sleeping under long-lasting
insecticide treated nets, despite the fact that MDA had
been suspended in the area for over 5 years [30]. The
apparent inefficiency in the transmission of LF in our
s t u d ya r e am a yb ep a r t l yd u et ot h ed i f f e r e n tv e c t o r -
parasite relationships observed in our study area where
Anopheles mosquitoes are the main vectors, compared
to Haiti where transmission is solely by Culex mosqui-
toes [31]. The phenomenon of facilitation exhibited by
Anopheles vectors is characterized by a dramatic reduc-
tion in transmission intensity following reduction in
microfilariae densities. In the case of Culex vectors,
which exhibit limitation, transmission persists at low
microfilariae densities [29]. Our results suggest that
national LF elimination programmes should be encour-
aged to continue provision of MDA albeit constraints
that may lead to postponement or even skipping of
MDA during some years. The sustained reduction of
microfilaraemia and antigenaemia in spite of missed
MDA rounds may be due a reduction in microfilariae
levels or vector densities below the threshold required
for transmission by Anopheles mosquitoes.
There have been intense efforts to reduce the burden
of malaria in Kenya through the use of effective control
tools, mainly ITNs and artemisinin-based combination
therapy (ACT). An increase in use of ITNs since 2002,
when our study was initiated, has been reported [32].
These malaria-specific control efforts most notable
being increased use of ITNs have been associated with a
decline in malaria in the area [33,34]. It is expected that
the massive distribution of ITNs may provide ancillary
health benefits beyond those directly associated to
reduction in malaria transmission. Some of these addi-
t i o n a lb e n e f i t sa r el i k e l yt oi n c l u d et h ec o n c o m i t a n t
Table 7 Mosquito net use in four study villages in a
survey conducted in 2008
Characteristic Village
Jilore Marikano Magongoloni Mkondoni All
No. of houses 36 39 40 40 155
Net use on night prior to survey
Yes (%) 26
(72.2)
21 (53.8) 33 (82.5) 29 (72.5) 109
(70.3)
No (%) 10
(27.8)
18 (46.2) 7 (17.5) 11 (27.5) 46
(29.7)
Frequency of net use per week
Every night 27
(75.0)
28 (71.8) 39 (97.5) 32 (80.0) 126
(81.3)
*Misses a few
nights
6
(16.7)
8 (20.5) 1 (2.5) 8 (20.0) 23
(14.8)
∞Misses most
nights
3 (8.3) 3 (7.7) 0 0 6 (3.9)
*Does not use net 1-2 nights per week
∞Does not use net 3 or more nights per week
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Previous reports from the Solomon Islands, where LF is
transmitted by Anopheles mosquitoes, showed that
malaria control efforts by spraying dichloro-diphenyl-tri-
chloroethane (DDT) resulted in reduced LF transmission
[35]. Also, a previous research study in Kwale District in
Coast Region, Kenya demonstrated that ITNs have ben-
eficial effect on transmission of LF [7].
The findings on LF infection in the examined children
born after implementation of the MDA suggest that
transmission of W. bancrofti infection in this area may
have been interrupted.
Conclusions
We conclude that the four rounds of MDA given over
an 8-year period had dramatic effect on reduction of
the prevalence of microfilariae (and circulating filarial
antigen), albeit MDA being missed in some years.
However, because of confounding variables such as
insecticide-treated bed nets (ITNs), it is difficult to
attribute the reduction to MDA alone as ITNs can
lead to a significant reduction in exposure to filariasis
vectors. We therefore recommend evaluation of the
role of vector control in LF elimination activities.
Addition of vector control methods such as ITNs
could provide the extra push needed to stop transmis-
sion of LF [18]. There is need to conduct additional
surveillance studies employing other sensitive tools
such as molecular xenomonitoring and antibody-based
assays to further assess status of LF transmission in
this study setting.
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